Alcohol polivinílico (PVA) para aglutinantes y recubrimientos de tabletas

In aqueous granulation processes requiring a binder that yields short disintegration times without sacrificing tensile strength, polyvinyl alcohol grades hydrolyzed to 88 mol% with a low viscosity designation are processed as a 12–15 wt% stock solution. The powder is dispersed in cold purified water under a high-torque propeller mixer at 400–600 rpm, then heated to a jacket temperature of 92 °C and held for 45 min until a clear, particulate-free liquid is obtained. After cooling to 35 °C, the solution is metered into a top-drive high-shear granulator (typical bowl volume 300–600 L, impeller tip speed 3–6 m/s, chopper 1500–2500 rpm) over an interval of 2–4 min. The binder quantity per dry blend mass is maintained at 2.0–3.5 wt% solid PVA, which corresponds to approximately 16–24 g of stock solution per kilogram of powder. Granule growth is terminated when the amperage draw of the impeller motor deviates by less than 5% across three consecutive seconds, a proxy for steady-state consistency. The wet mass is then delumped through a conical mill fitted with a 2.0 mm rasp screen and transferred to a fluid-bed dryer operating with an inlet air temperature of 60 °C and a product temperature endpoint of 38–42 °C. Final loss on drying is specified at 1.5–2.0%, measured by a halogen moisture analyzer at 105 °C until constant mass. Compression on a rotary tablet press at a main force of 8–14 kN for round concave tooling (10 mm diameter) generates immediate-release tablets with a crushing strength of 7–10 kP and a friability below 0.8% when tested per USP <1216>. Disintegration time in 900 mL deionized water at 37 °C using disks remains below 5 min (USP <701>). The grade preferred in this application is a fully compliant material per the Polyvinyl Alcohol monograph USP-NF with a viscosity of 4.0–6.0 mPa·s (4% solution, 20 °C) and residual vinyl acetate monomers below 0.3% w/w (Ph.Eur. limit). The same substance appears in the FDA Inactive Ingredient Database at a maximum per-tablet quantity of 25 mg for oral tablets when used as a binder. Typical end-products include directly compressible paracetamol 500 mg tablets, calcium carbonate antacid tablets, and multi-vitamin cores, where the low-viscosity PVA reduces elastic recovery during decompression and prevents capping.

Why Do Direct Compression Trials with PVA 26-88 Outperform Hypromellose in Plastic Deformation Metrics?

The substitution of hypromellose with polyvinyl alcohol 26-88 (viscosity 20–30 mPa·s, 4% solution) as a dry binder in direct compression originates from the polymer’s distinct plastic deformation behavior under compaction load. Milled PVA particles with a volume mean diameter d(0.5) below 125 µm are blended with the active ingredient and a disintegrant (crospovidone Type A, 5% w/w) in a diffusion mixer for 15 min at 25 rpm. The binder level is restricted to 3–4 wt% of the total blend weight, as higher concentrations generate tablet surfaces with excessive gloss that retard breakup. True density of the polymer phase, determined by helium pycnometry at 1.26 g/cm³, remains constant regardless of compression force; this attribute permits particle rearrangement and cold flow at pressures above 120 MPa without brittle fracture of the binder domains. Scanning electron micrographs of post-compression fracture planes confirm a continuous binder network between API crystals when the compaction pressure reaches 150 MPa. Tablets produced at this pressure display a tensile strength of 1.8–2.2 MPa and a disintegration time of 8–12 min in 0.1 N HCl at 37 °C, meeting the requirements for high-dose immediate-release formulations such as rifampicin 600 mg tablets where physical separation of the friable drug particles from the punch face is critical. The formulation must comply with FDA 21 CFR 177.1670 (optional, for incidental food contact) and the IIG listing that records a maximum daily exposure of 214 mg of PVA for oral solid dosage forms. In-process control enforces blend uniformity with a relative standard deviation below 3.0% for the active component across 10 stratified sampling points. This method is incompatible with lubricants containing high free fatty acid concentrations, as the plastic flow of PVA is suppressed by stearic acid films above 0.8 wt%, causing edge chipping during decompression.In aqueous film-coating of immediate-release tablets, a fully hydrolyzed polyvinyl alcohol with a 4% solution viscosity of 15–20 mPa·s is dispersed in purified water at 12.0 wt% solids together with polyethylene glycol 6000 (2.5 wt% of dry formulation) and talc (1.0 wt% of dry formulation). The dispersion is homogenized with a rotor-stator at 8000 rpm for 10 min, then de-aerated under vacuum. Coating is applied in a fully perforated side-vented pan (O’Hara Labcoat III, 24-inch diameter) charged with 15 kg of biconvex placebo cores. Inlet air temperature is fixed at 68 °C, exhaust air at 48 °C, and tablet bed temperature at 40 °C as measured by an infrared probe observing the cascading mass. Atomization air pressure of 1.8 bar generates droplets with a Sauter mean diameter of 22–26 µm, while pan speed is held at 10 rpm and spray rate ramps from 8 g/min/kg to 15 g/min/kg over the first 20% of weight gain. A 3.0–4.0% weight gain produces a film thickness of 45–60 µm measured by micrometer at the tablet band. The coating system conforms to USP <2040> for delayed release of the active only where a functional subcoat exists; for purely aesthetic or light-protective coatings, disintegration time shifts by less than 30 s relative to uncoated cores. PVA-based immediate-release film coatings are listed in the IIG at a max per-dose limit of 12 mg and are typically marketed as pre-formulated systems such as Opadry® II series, which incorporate partial substitution of titanium dioxide (20–30% of dry coat weight) for opacity. The coating process is validated by demonstrating color uniformity via a spectrophotometer with a ΔE(CIE76) ≤ 1.0 across 20 randomly sampled tablets. Critical failure mode includes seam splitting at the tablet edge when the pan exhaust humidity exceeds 15 g/kg, a condition that accelerates PVA surface skinning before complete inter-tablet coverage.

When Pediatric Compliance Requires Masking of Bitter APIs, PVA-Based Seal Coats Precede Sugar Coating

Pediatric paracetamol 250 mg tablets destined for sugar coating receive a pre-coat seal layer composed of a 10.0 wt% PVA 18-88 solution containing 0.5 wt% polysorbate 80 (based on dry polymer) and 2.0 wt% micronized talc as a separation agent. The seal coat is applied in a coating pan without side vents, using a low-pressure (0.8 bar) airless spray system at a bed temperature of 35–38 °C. A weight gain of 2.0% is sufficient to block migration of the bitter API into the subsequent sugar layers, a phenomenon verified by HPLC analysis of the outer sugar shell showing paracetamol levels below 0.05 µg/cm² after 30 days of storage at 40 °C/75% RH. The seal coat also reduces moisture vapor transmission rate by 40% relative to an uncoated core when measured gravimetrically at 25 °C/75% RH per ASTM E96 (Cup Method). Regulatory acceptance for pediatric use rests on compliance with the Ph.Eur. monograph and confirmation that the residual vinyl acetate and methanol contents are below 0.3% and 0.5% respectively, as determined by headspace gas chromatography per Ph.Eur. 2.4.25. The coated cores are subsequently built up with 15–25 alternating layers of sucrose solution and dusting powder in classic hard sugar-coating kettles. Terminal products include chewable vitamin C tablets and pediatric ibuprofen tablets that must withstand brief oral residence without releasing objectionable flavor.

PVA Grade Selection Matrix for Pharmaceutical Solid Dosage Processing

Application	PVA Grade Designation	4% Aqueous Viscosity (mPa·s, 20°C)	Hydrolysis Degree (mol%)	Typical Binder/Coating Level (wt% of dry mass)	Critical Processing Window
Wet granulation (high-shear)	18-88	4.0–6.0	87–89	2.0–3.5	Granulation endpoint ±3% amperage variance
Direct compression dry binder	26-88	20–30	87–89	3.0–4.0	Compaction force 130–170 MPa
Aqueous film coating (immediate release)	05-88 or 18-88	4–6 or 15–20	86–89	2.5–4.0 weight gain	Exhaust humidity ≤15 g/kg
Pediatric seal coating	18-88	4.0–6.0	87–89	2.0 weight gain	Bed temperature 34–39 °C
Melt extrusion carrier	26-88 + plasticizer	20–30	87–89	50–70 (polymer phase)	Extruder zone 170–205 °C, torque 40–70%

PVA as a Carrier Matrix for Hot-Melt Extruded Amorphous Solid Dispersions: Processing Window Limitations

Polyvinyl alcohol 26-88 is co-processed with sorbitol (30 wt% of the polymer phase) in a co-rotating twin-screw extruder (Thermo Fisher Pharma 16 mm, L/D 40:1) to generate a glassy dispersion of a BCS Class II drug such as griseofulvin at a 20 wt% drug load. The premix is fed gravimetrically at 1.0 kg/h with a screw speed of 200–300 rpm; barrel zones are set to 140/170/195/195/190 °C from feed to die. Melt pressure at the die plate is maintained below 35 bar to avoid shear-induced degradation of PVA, which can release acetic acid and corrode die inserts. The extrudate is pelletized and milled to a granule fraction 250–850 µm, then blended with 5% croscarmellose sodium and compressed at 10 kN into tablets containing a label dose of 125 mg. Non-sink dissolution in 900 mL of simulated gastric fluid (USP <711> Apparatus II, 75 rpm) yields 85% drug release within 30 min, a sixfold improvement over crystalline drug dispersion in an identically formulated physical blend. The amorphous state is verified by powder X-ray diffraction, with no detectable recrystallization peaks after 3 months at 40 °C/75% RH in sealed HDPE bottles containing a molecular sieve desiccant. The system is constrained by a melt viscosity window: at temperatures exceeding 210 °C, the complex viscosity drops below 800 Pa·s (measured by a slit rheometer attached at the die), causing inefficient mixing and drug domain size non-uniformity. Residual crystallinity from partially melted PVA domains occurs when the residence time is less than 60 s, dictating a minimum extruder filling ratio of 40%. Complying with Ph.Eur. Polyvinyl Alcohol monograph, the total ash and heavy metal content must be below 0.1% and 10 ppm respectively, to avoid catalyzing chain scission during extrusion.

Incorporating PVA into Orally Disintegrating Tablets via Lyophilization and Molding Techniques

A 2.0 wt% aqueous solution of PVA 18-88, co-dissolved with gelatin (4.0 wt%) and mannitol (3.0 wt%), is dosed into blister pockets at 500 mg aliquots and freeze-dried in a shelf lyophilizer with a primary drying cycle at -40 °C and 0.2 mbar for 24 h, followed by secondary drying at 25 °C until a residual moisture of 1.5% is attained. The resulting wafers disintegrate in 3–7 s when placed on the tongue, as verified by volunteer in-vivo disintegration tests referenced against the <2 mL saliva volume available in a resting oral cavity. The PVA network contributes mechanical strength without gelling in contact with cold water, unlike higher viscosity grades which require elevated temperatures to fully hydrate. Compliance is assessed per USP <701> disintegration test with a 0.01 N HCl medium at 37 °C; all units must disintegrate completely within 30 s. A complementary molded ODT process for loperamide 2 mg tablets uses a hydroalcoholic PVA binder (1.5% w/w solids) applied to a wet mass compressed at 60 N and dried in a vacuum oven at 50 °C. The resulting tablets exhibit a porosity of 45% measured by mercury intrusion porosimetry and a crushing strength of 15 N. The PVA grade used must contain no detectable residual methanol by USP <467> Class 2 residual solvent testing, as the product is intended for prolonged oral retention. Terminal dosage forms cover anti-allergy ODT strips and emergency antiemetic wafers that rely on PVA’s neutral taste and rapid dissolution profile without generating a gummy after-feel.